Explore 3 Stock Ideas & Industry Insights Download Free Report

Earnings

Immix Biopharma (NASDAQ:IMMX) Stock: Q3 2026 Earnings, NXC-201 Trial Update and Offering Proceeds

Research and development expense was US$5,542,281, versus US$4,584,131, which the company tied to its NEXICART-2 clinical trial and other CAR-T clinical andManufacturingactivities. It noted that no CIRM grant reimbursements were received in the quarter, compared with approximately US$1.1 million a year earlier, which had …

Nitish Kishor | 14 November 2026

Benitec Biopharma (NASDAQ:BNTC) Stock: Fiscal Q1 2027 Earnings, BB-301 Trial Progress and Cash Position

General and administrative expenses were US$5,859 thousand, versus US$6,433 thousand. The company tied the decrease primarily to a US$0.7 million decrease in stock-based compensation. Total operating expenses were US$14,477 thousand versus US$9,803 thousand, and the loss from operations equaled those amounts.

Nitish Kishor | 14 November 2026

Tvardi Therapeutics (NASDAQ:TVRD) Stock: Q3 2026 Earnings, TTI-101 Trial Timeline and At-the-Market Sales

The company tied the HCC trial increase to changes in total trial costs from trial scope changes, and the TTI-109 decrease to higher costs in the third quarter of 2025 when its healthy volunteer study began. General and administrative expenses were US$1,854 thousand, versus …

Nitish Kishor | 14 November 2026

Owlet (NYSE:OWLT) Stock: Q3 2026 Earnings, Subscription Revenue and Camera Cable Guard Safety Update

Subscription revenue was US$3.6 million, versus US$1.5 million. The company said it ended the quarter with more than 142,000 paying Owlet360 subscribers. Revenue for the nine months was US$86.7 million, versus US$79.6 million.

Nitish Kishor | 14 November 2026

PAVmed (NASDAQ:PAVM) Stock: Q3 2026 Earnings, EsoGuard Medicare Payments and Veris Update

The net loss before noncontrolling interest and preferred dividends was approximately US$13 million, versus US$6 million a year earlier. Net loss attributable to PAVM common stockholders was US$11.8 million, which management said remains subject to the finalDebtvaluation analysis. The non-GAAP adjusted loss was US$1.2 …

Nitish Kishor | 14 November 2026

Biofrontera (NASDAQ:BFRI) Stock: Q3 2026 Earnings, Ameluz sBCC Approval and ITC Matter Update

Net loss was US$6.4 million, or US$(0.42) per share, versus US$6.6 million, or US$(0.62) per share, a year earlier. Adjusted EBITDA, a non-GAAP measure, was US$(5.5) million, versus US$(6.0) million. For the nine months ended September 30, net product revenue was US$31.2 million, up …

Nitish Kishor | 14 November 2026

Allarity Therapeutics (NASDAQ:ALLR) Stock: Q3 2026 Earnings, Stenoparib Phase 3 Manufacturing and Financing Update

Research and development expenses were US$4,219 thousand versus US$1,203 thousand, an increase of US$3.0 million that the company attributed to Phase 3 drug manufacturing costs and continuation of the Phase 2 clinical trial of stenoparib. A one-time expense of US$3.2 million for manufacturing of …

Nitish Kishor | 14 November 2026

Annovis Bio (NYSE:ANVS) Stock: Preliminary Q3 2026 Cash Estimate Ahead of Quarterly Financial Statements

The company's common stock is listed on the New York Stock Exchange. The report was signed by Chief Executive Officer Maria Maccecchini.

Nitish Kishor | 14 November 2026

Why Is Newsmax (NYSE:NMAX) Up 34.85% After Q3 Profit Helped by a USD 14 Million Fee?

Adjusted EBITDA was USD 19.0 million, but only USD 5.0 million excluding the fee, against a loss of USD 0.9 million a year earlier. Affiliate fee revenue rose 77.4% to USD 14.3 million, helped by new carriage agreements with independent cable operators and the …

Vinay Lochav | 13 November 2026

Did a Record USD 1.09 Billion Profit Push Nu Holdings (NYSE:NU) Up 7.57%?

In Mexico, Nu added 870 thousand customers in its first quarter as a bank, reaching 16.6 million. In Brazil, where customers number about 119.9 million (calculated from the totals), it serves 65% of adults, the activity rate hit a record 86.3% and personal-loan originations …

Vinay Lochav | 13 November 2026
Support

Hi! How can we help you today?

Loading…